Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexylcaine is a short-acting local anesthetic of the benzoate ester class, primarily used for surface anesthesia of mucous membranes. Its mechanism of action involves inhibition of sodium influx through voltage-gated sodium channels in neuronal cell membranes, thereby blocking nerve conduction and preventing the generation and propagation of action potentials. This results in localized numbness and pain relief. Hexylcaine has been used in dental procedures and minor surgical interventions but has been discontinued in the US market. Overdose can cause symptoms such as headache, tinnitus, perioral numbness, convulsions, respiratory depression, and cardiac dysfunction[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexylcaine.